[What success does L-Dopa have in the treatment of parkinsonian akinesia?].
D000368:Aged; D001712:Biperiden / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D003891:Desipramine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage*; D004296:Dopa Decarboxylase / Q000378:metabolism; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications*
D010276:Parasympatholytics; D001712:Biperiden; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004296:Dopa Decarboxylase; D003891:Desipramine
Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?